D-penicillamine treatment for chronic sensory ataxic neuropathy associated with Sjögren's syndrome.
Beneficial treatment has not been established for chronic sensory ataxic neuropathy associated with Sjögren's syndrome (CSAN-SS). We describe two patients with CSAN-SS who clinically improved in response to D-penicillamine treatment. Their neuropathic symptoms were lessened after D-penicillamine, and the results of electrophysiologic studies support the clinical improvement. D-Penicillamine can be considered a potentially beneficial agent in the treatment of CSAN-SS.
Asahina
M
M
Department of Neurology, School of Medicine, Chiba University, Japan.
Kuwabara
S
S
Asahina
M
M
Nakajima
M
M
Hattori
T
T
D000328:Adult; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001259:Ataxia / Q000188:drug therapy* / Q000209:etiology; D005073:Evoked Potentials, Somatosensory; D005260:Female; D006801:Humans; D008475:Median Nerve / Q000503:physiopathology; D009431:Neural Conduction / Q000187:drug effects* / Q000502:physiology; D009460:Neurologic Examination; D010396:Penicillamine / Q000627:therapeutic use*; D012859:Sjogren's Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D013497:Sural Nerve / Q000503:physiopathology; D014459:Ulnar Nerve / Q000503:physiopathology
D018501:Antirheumatic Agents; D010396:Penicillamine